181 related articles for article (PubMed ID: 30251237)
1. Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?
Lawthom C; Peltola J; McMurray R; Dodd E; Villanueva V
Neurol Ther; 2018 Dec; 7(2):195-206. PubMed ID: 30251237
[TBL] [Abstract][Full Text] [Related]
2. Practical guidance and considerations for transitioning patients from oxcarbazepine or carbamazepine to eslicarbazepine acetate--Expert opinion.
Peltola J; Holtkamp M; Rocamora R; Ryvlin P; Sieradzan K; Villanueva V
Epilepsy Behav; 2015 Sep; 50():46-9. PubMed ID: 26114438
[TBL] [Abstract][Full Text] [Related]
3. Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy.
Lattanzi S; Brigo F; Cagnetti C; Verrotti A; Zaccara G; Silvestrini M
Core Evid; 2018; 13():21-31. PubMed ID: 29563858
[TBL] [Abstract][Full Text] [Related]
4. Transition from oxcarbazepine to eslicarbazepine acetate: A single center study.
Mäkinen J; Rainesalo S; Peltola J
Brain Behav; 2017 Mar; 7(3):e00634. PubMed ID: 28293474
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study.
Villanueva V; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López González FJ; Flores J; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A
Epilepsy Res; 2014 Sep; 108(7):1243-52. PubMed ID: 24908564
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice.
Rocamora R; Peltola J; Assenza G; McMurray R; Villanueva V
Seizure; 2020 Feb; 75():121-128. PubMed ID: 31981862
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and drug interactions of eslicarbazepine acetate.
Bialer M; Soares-da-Silva P
Epilepsia; 2012 Jun; 53(6):935-46. PubMed ID: 22612290
[TBL] [Abstract][Full Text] [Related]
8. Carbamazepine-, Oxcarbazepine-, Eslicarbazepine-Associated Movement Disorder: A Literature Review.
Rissardo JP; Caprara ALF
Clin Neuropharmacol; 2020; 43(3):66-80. PubMed ID: 32384309
[TBL] [Abstract][Full Text] [Related]
9. EPICON consensus: recommendations for proper management of switching to eslicarbazepine acetate in epilepsy.
Villanueva V; Ojeda J; Rocamora RA; Serrano-Castro PJ; Parra J; Rodríguez-Uranga JJ; Bathal H; Viteri C
Neurologia (Engl Ed); 2018 Jun; 33(5):290-300. PubMed ID: 27349151
[TBL] [Abstract][Full Text] [Related]
10. Antiepileptic drugs-induced hyponatremia: Review and analysis of 560 hospitalized patients.
Intravooth T; Staack AM; Juerges K; Stockinger J; Steinhoff BJ
Epilepsy Res; 2018 Jul; 143():7-10. PubMed ID: 29631131
[TBL] [Abstract][Full Text] [Related]
11. Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy.
Tambucci R; Basti C; Maresca M; Coppola G; Verrotti A
Neuropsychiatr Dis Treat; 2016; 12():1251-60. PubMed ID: 27307737
[TBL] [Abstract][Full Text] [Related]
12. Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study.
Schmid E; Kuchukhidze G; Kirschner M; Leitinger M; Höfler J; Rohracher A; Kalss G; Wendling AS; Steinhoff BJ; Trinka E
Acta Neurol Scand; 2017 Apr; 135(4):449-453. PubMed ID: 27444636
[TBL] [Abstract][Full Text] [Related]
13. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.
Shorvon SD; Trinka E; Steinhoff BJ; Holtkamp M; Villanueva V; Peltola J; Ben-Menachem E
J Neurol; 2017 Mar; 264(3):421-431. PubMed ID: 28101651
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
Elger C; Bialer M; Falcão A; Vaz-da-Silva M; Nunes T; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Aug; 54(8):1453-61. PubMed ID: 23758485
[TBL] [Abstract][Full Text] [Related]
15. [Long-term effects of dibenzazepines on metabolic parameters: retrospective comparison of carbamazepine, oxcarbazepine and eslicarbazepine acetate in the real world].
Ley M; Principe A; Rocamora R
Rev Neurol; 2020 Jul; 71(2):54-60. PubMed ID: 32627160
[TBL] [Abstract][Full Text] [Related]
16. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.
Nunes T; Rocha JF; Falcão A; Almeida L; Soares-da-Silva P
Epilepsia; 2013 Jan; 54(1):108-16. PubMed ID: 22812691
[TBL] [Abstract][Full Text] [Related]
17. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Pharmacokinetic Interactions With Eslicarbazepine Acetate Versus Oxcarbazepine and Carbamazepine in Clinical Practice.
Johannessen Landmark C; Svendsen T; Dinarevic J; Kufaas RF; Reimers A; Brodtkorb E; Baftiu A; Burns ML; Johannessen SI
Ther Drug Monit; 2016 Aug; 38(4):499-505. PubMed ID: 27414974
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of eslicarbazepine acetate monotherapy in patients converting from carbamazepine.
Pazdera L; Sperling MR; Harvey JH; Sam MC; Strom LA; Blum D; Grinnell T; Cheng H
Epilepsia; 2018 Mar; 59(3):704-714. PubMed ID: 29450890
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series.
Gómez-Ibáñez A; Serratosa JM; Guillamón E; Garcés M; Giráldez BG; Toledo M; Salas-Puig J; López-González FJ; Rodríguez-Uranga J; Castillo A; Mauri JA; Camacho JL; López-Gomáriz E; Giner P; Torres N; Palau J; Molins A; Villanueva V
Seizure; 2017 May; 48():53-56. PubMed ID: 28419947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
